利厄替尼治疗EGFR T790M突变阳性NSCLC关键IIB期临床研究中，共计入组了 301 例经既往EGFR-TKI治疗后进展的EGFR T790M突变阳性或原发性EGFR T790M突变阳性局部 ...

今日，恒瑞医药宣布，公司收到国家药品监督管理局（以下简称 “国家药监局”）核准签发关于注射用SHR-9839(sc)的《药物临床试验批准通知书》，将 ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and toxicity management in patients with EGFR-mutated non–small cell lung ...

Several targets almost fulfill this requisite: tenascin-C, podoplanin/aggrus, EGF receptor (EGFR), EGFRvIII ... extradomain B of fibronectin, integrin α v β 3, histone H1 complexed to ...

It shows how adjusting eGFR results for body surface may improve decision results. The National Kidney Foundation published a consensus document that advocates transition to race-free eGFR ...

Results from the Phase III MARIPOSA trial demonstrated the combination of Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) significantly improves overall survival compared to the current ...

In diabetic nephropathy, albuminuria first appears, leading to excessive filtration and eventually a decrease in GFR. In the elderly, however, excessive filtration cannot be detected due to age ...

2024 年，非小细胞肺癌（NSCLC）治疗领域迎来了累累硕果。尤其是针对 EGFR 突变 III 期不可切除 NSCLC 的靶向巩固治疗研究，取得了令人振奋的突破性 ...

It was also confirmed that HDCA inhibited the Epiregulin (EREG)/Epidermal Growth Factor Receptor (EGFR) pathway by activating FXR, and a negative correlation between FXR and EREG was analyzed in CRC ...